Atara Biotherapeutics Inc. | Mutual Funds
Mutual Funds that own Atara Biotherapeutics Inc.
Fidelity Select Biotechnology Portfolio
1,687,168
3.72%
-90,592
0.75%
07/31/2018
SPDR S&P Biotech ETF
1,443,845
3.18%
3,714
1.01%
09/06/2018
Eagle Small Cap Growth Fund
1,286,445
2.84%
0
0.91%
06/29/2018
Fidelity Select Health Care Portfolio
1,080,000
2.38%
0
0.57%
07/31/2018
iShares Russell 2000 ETF
851,089
1.88%
-456
0.07%
09/06/2018
Vanguard Total Stock Market Index Fund
824,030
1.82%
0
0%
07/31/2018
T Rowe Price Health Sciences Fund
772,237
1.7%
7,840
0.25%
06/30/2018
Vanguard Extended Market Index Fund
580,887
1.28%
4,400
0.03%
07/31/2018
iShares Nasdaq Biotechnology ETF
509,431
1.12%
-6,657
0.21%
09/06/2018
Fidelity Advisor Health Care Fund
500,000
1.1%
0
0.6%
07/31/2018
| Address |
611 Gateway Boulevard
South San Francisco California 94080
United States
|
|
Employees
|
- |
| Website |
http://www.atarabio.com |
| Updated |
07/08/2019 |
| Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. The company was founded by Isaac E. |
